CY1124478T1 - Ετεροκυκλικες ενωσεις ως αναστολεις της κiνασης ret - Google Patents

Ετεροκυκλικες ενωσεις ως αναστολεις της κiνασης ret

Info

Publication number: CY1124478T1
Authority: CY; Cyprus
Prior art keywords: kinase inhibitors; ret kinase; heterocyclic compounds; ret; compounds
Prior art date: 2016-04-15

Application number

CY20211100784T

Other languages

Greek (el)

English (en)

Inventor

Allan Jordan

Rebecca NEWTON

Bohdan Waszkowycz

Silvia PAOLETTA

Euan Alexander Fraser Fordyce

George Hynd

Jonathan Mark Sutton

Original Assignee

Cancer Research Technology Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-04-15

Filing date

2021-09-06

Publication date

2022-07-22

2021-09-06 Application filed by Cancer Research Technology Limited filed Critical Cancer Research Technology Limited

2022-07-22 Publication of CY1124478T1 publication Critical patent/CY1124478T1/el

Links

150000002391 heterocyclic compounds Chemical class 0.000 title 1
229940043355 kinase inhibitor Drugs 0.000 title 1
239000003757 phosphotransferase inhibitor Substances 0.000 title 1
108091000080 Phosphotransferase Proteins 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
230000000694 effects Effects 0.000 abstract 2
102000020233 phosphotransferase Human genes 0.000 abstract 2
208000002925 dental caries Diseases 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000002062 proliferating effect Effects 0.000 abstract 1
238000001890 transfection Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pyridine Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CY20211100784T 2016-04-15 2021-09-06 Ετεροκυκλικες ενωσεις ως αναστολεις της κiνασης ret CY1124478T1 (el)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB201606631		2016-04-15
GB201619277		2016-11-14
PCT/GB2017/051076 WO2017178844A1 (en)	2016-04-15	2017-04-18	Heterocyclic compounds as ret kinase inhibitors

Publications (1)

Publication Number	Publication Date
CY1124478T1 true CY1124478T1 (el)	2022-07-22

Family

ID=58633035

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CY20211100784T CY1124478T1 (el)	2016-04-15	2021-09-06	Ετεροκυκλικες ενωσεις ως αναστολεις της κiνασης ret

Country Status (23)

Country	Link
US (4)	US10954241B2 (2)
EP (2)	EP3442980B1 (2)
JP (3)	JP6943876B2 (2)
KR (3)	KR102706837B1 (2)
CN (2)	CN109195972B (2)
AU (3)	AU2017250448C1 (2)
BR (2)	BR122023026297A2 (2)
CY (1)	CY1124478T1 (2)
DK (1)	DK3442980T3 (2)
ES (1)	ES2886587T3 (2)
HR (1)	HRP20211362T1 (2)
HU (1)	HUE056135T2 (2)
IL (3)	IL289793B2 (2)
LT (1)	LT3442980T (2)
MX (2)	MX387394B (2)
PL (1)	PL3442980T3 (2)
PT (1)	PT3442980T (2)
RS (1)	RS62322B1 (2)
RU (1)	RU2742115C2 (2)
SG (2)	SG10201911665UA (2)
SI (1)	SI3442980T1 (2)
SM (1)	SMT202100538T1 (2)
WO (1)	WO2017178844A1 (2)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ME03376B (me)	2010-05-20	2020-01-20	Array Biopharma Inc	Makrociklička jedinjenja kао inhibiтori trk kinaze
BR112018000808A2 (pt)	2015-07-16	2018-09-04	Array Biopharma Inc	compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase
SI3371171T1 (sl)	2015-11-02	2024-03-29	Blueprint Medicines Corporation	Inhibitorji ret
WO2017178844A1 (en) *	2016-04-15	2017-10-19	Cancer Research Technology Limited	Heterocyclic compounds as ret kinase inhibitors
SI3442535T1 (sl) *	2016-04-15	2023-01-31	Cancer Research Technology Limited	Heterociklične spojine kot zaviralci RET-kinaze
TWI752098B (zh)	2016-10-10	2022-01-11	美商亞雷生物製藥股份有限公司	作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
TWI704148B (zh)	2016-10-10	2020-09-11	美商亞雷生物製藥股份有限公司	作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
WO2018136663A1 (en)	2017-01-18	2018-07-26	Array Biopharma, Inc.	Ret inhibitors
WO2018136661A1 (en)	2017-01-18	2018-07-26	Andrews Steven W	SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS
JOP20190213A1 (ar)	2017-03-16	2019-09-16	Array Biopharma Inc	مركبات حلقية ضخمة كمثبطات لكيناز ros1
GB201705971D0 (en)	2017-04-13	2017-05-31	Cancer Res Tech Ltd	Inhibitor compounds
TWI876442B (zh)	2017-10-10	2025-03-11	美商絡速藥業公司	6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh)	2017-10-10	2023-02-01	美商亞雷生物製藥股份有限公司	6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
JP7060694B2 (ja)	2018-01-18	2022-04-26	アレイバイオファーマインコーポレイテッド	Ｒｅｔキナーゼ阻害剤としての置換ピロロ［２，３－ｄ］ピリミジン化合物
US11472802B2 (en)	2018-01-18	2022-10-18	Array Biopharma Inc.	Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
EP3740490A1 (en) *	2018-01-18	2020-11-25	Array Biopharma, Inc.	Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
PE20210096A1 (es)	2018-04-03	2021-01-12	Blueprint Medicines Corp	Inhibidor de ret para uso en tratar cancer que tiene una alteracion de ret
IL277408B2 (en) *	2018-04-05	2024-08-01	Merck Patent Gmbh	Heteroaryl compounds as IRAK type II inhibitors and their use
CN112996794A (zh)	2018-09-10	2021-06-18	阿雷生物药品公司	作为ret激酶抑制剂的稠合杂环化合物
MX2021003904A (es)	2018-10-05	2021-10-26	Annapurna Bio Inc	Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor apj.
WO2020200316A1 (zh) *	2019-04-03	2020-10-08	南京明德新药研发有限公司	作为ret抑制剂的吡唑并吡啶类化合物及其应用
JP7732668B2 (ja) *	2019-08-05	2025-09-02	北京志健金瑞生物医▲薬▼科技有限公司	窒素含有多環式縮合環系化合物、その薬学的組成物、製造方法及び用途
US12565481B2 (en)	2020-02-20	2026-03-03	Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Baiyunshan Pharmaceutical General Factory	6,7-dimethoxy-3-(pyridin-2-yl)quinoline compounds for inhibiting RET
EP4146654A1 (en) *	2020-05-07	2023-03-15	Adorx therapeutics Limited	Antagonists of the adenosine a2a receptor
EP4157829A1 (en)	2020-05-29	2023-04-05	Blueprint Medicines Corporation	Solid forms of pralsetinib
CN113214294A (zh) *	2020-06-10	2021-08-06	深圳铂立健医药有限公司	三环化合物、药物组合物及其应用
KR20230104781A (ko)	2020-10-05	2023-07-10	인라이븐 테라퓨틱스, 인크.	Bcr-abl 티로신 키나아제의 억제를 위한 5- 및 6-아자인돌 화합물
TWI887510B (zh) *	2020-12-22	2025-06-21	美商基利科學股份有限公司	6-取代之吲哚化合物
TWI838670B (zh) *	2020-12-22	2024-04-11	美商基利科學股份有限公司	經取代之吲哚化合物
KR20230171469A (ko)	2021-04-16	2023-12-20	길리애드 사이언시즈, 인코포레이티드	티에노피롤 화합물
CN113248518B (zh) *	2021-06-21	2022-03-25	山东大学	嘧啶哌嗪类衍生物及其制备方法与应用
EP4398989A1 (en)	2021-09-10	2024-07-17	Gilead Sciences, Inc.	Thienopyrrole compounds
EP4415718A1 (en) *	2021-10-15	2024-08-21	Stemline Therapeutics Inc.	Inhibitors of mutant ret kinases for use in treating cancer
WO2024151519A2 (en) *	2023-01-09	2024-07-18	University Of Florida Research Foundatin, Incorporated	Pparg modulators
AR133526A1 (es) *	2023-08-09	2025-10-08	Daewoong Pharmaceutical Co Ltd	Nuevo compuesto, y una composición farmacéutica para la prevención o el tratamiento del cáncer o tumores que comprende el mismo

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0322779A3 (en)	1987-12-29	1991-05-08	Yoshitomi Pharmaceutical Industries, Ltd.	Benzolactam compounds and pharmaceutical uses thereof
US5480883A (en)	1991-05-10	1996-01-02	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US6383790B1 (en) *	1999-01-11	2002-05-07	Princeton University	High affinity protein kinase inhibitors
US7119200B2 (en)	2002-09-04	2006-10-10	Schering Corporation	Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7429596B2 (en)	2003-06-20	2008-09-30	The Regents Of The University Of California	1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
EP1831225A2 (en)	2004-11-19	2007-09-12	The Regents of the University of California	Anti-inflammatory pyrazolopyrimidines
WO2006092430A1 (de)	2005-03-03	2006-09-08	Universität des Saarlandes	Selektive hemmstoffe humaner corticoidsynthasen
ES2365869T3 (es) *	2005-11-17	2011-10-11	OSI Pharmaceuticals, LLC	COMPUESTOS BICÍCLICOS FUSIONADOS INHIBIDORES DE LA mTOR.
AR057960A1 (es)	2005-12-02	2007-12-26	Osi Pharm Inc	Inhibidores de proteina quinasa biciclicos
ES2545907T3 (es)	2005-12-29	2015-09-16	Abbvie Inc.	Inhibidores de proteína quinasa
GB0610242D0 (en)	2006-05-23	2006-07-05	Novartis Ag	Organic compounds
JP2008063278A (ja)	2006-09-07	2008-03-21	Fujifilm Finechemicals Co Ltd	１−ピリジン−４−イル−インドール類の製造方法
DK2526933T3 (en)	2006-09-22	2015-05-18	Pharmacyclics Inc	Inhibitors of Bruton's tyrosine kinase
US20090274698A1 (en) *	2007-07-06	2009-11-05	Shripad Bhagwat	Combination anti-cancer therapy
US8193182B2 (en)	2008-01-04	2012-06-05	Intellikine, Inc.	Substituted isoquinolin-1(2H)-ones, and methods of use thereof
MX2010007419A (es)	2008-01-04	2010-11-12	Intellikine Inc	Ciertas entidades quimicas, composiciones y metodos.
EP2252293B1 (en) *	2008-03-14	2018-06-27	Intellikine, LLC	Kinase inhibitors and methods of use
US20110224223A1 (en) *	2008-07-08	2011-09-15	The Regents Of The University Of California, A California Corporation	MTOR Modulators and Uses Thereof
BRPI0915231A2 (pt) *	2008-07-08	2018-06-12	Intellikine Inc	compostos inibidores de quinase e métodos de uso
CA2738429C (en)	2008-09-26	2016-10-25	Intellikine, Inc.	Heterocyclic kinase inhibitors
WO2010059593A1 (en)	2008-11-18	2010-05-27	Intellikine, Inc.	Methods and compositions for treatment of ophthalmic conditions
KR101061599B1 (ko) *	2008-12-05	2011-09-02	한국과학기술연구원	비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물
NZ599830A (en)	2009-11-05	2014-08-29	Rhizen Pharmaceuticals Sa	Novel kinase modulators
EP2528919B1 (en)	2010-01-28	2016-11-02	University of Washington	Compositions and methods for treating toxoplasmosis. cryptosporidiosis and other apicomplexan protozoan related diseases
US9765037B2 (en)	2010-01-28	2017-09-19	University Of Washington Through Its Center For Commercialization	Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases
UY33288A (es) *	2010-03-25	2011-10-31	Glaxosmithkline Llc	Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico
WO2011153553A2 (en)	2010-06-04	2011-12-08	The Regents Of The University Of California	Methods and compositions for kinase inhibition
US20130296316A1 (en)	2010-07-09	2013-11-07	Michael P. Pollastri	Antiparasitic Agents Based On mTOR Inhibitors
US9295673B2 (en)	2011-02-23	2016-03-29	Intellikine Llc	Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
JP6047149B2 (ja)	2011-05-04	2016-12-21	インテリカイン，エルエルシー	併用の医薬組成物およびその使用
EP2741747A1 (en)	2011-08-10	2014-06-18	Novartis Pharma AG	JAK P13K/mTOR COMBINATION THERAPY
CA2846496C (en) *	2011-09-02	2020-07-14	The Regents Of The University Of California	Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
WO2013070976A1 (en)	2011-11-08	2013-05-16	Intellikine, Llc	Treatment regimens using multiple pharmaceutical agents
JP6130391B2 (ja)	2011-11-23	2017-05-17	インテリカイン，エルエルシー	Ｍｔｏｒ阻害剤を使用する強化された治療レジメン
US8501724B1 (en)	2012-01-31	2013-08-06	Pharmacyclics, Inc.	Purinone compounds as kinase inhibitors
US8889730B2 (en)	2012-04-10	2014-11-18	Pfizer Inc.	Indole and indazole compounds that activate AMPK
US9738610B2 (en)	2012-09-24	2017-08-22	Whitehead Institute For Biomedical Research	Indazole derivatives and uses thereof
GB201217285D0 (en)	2012-09-27	2012-11-14	Univ Central Lancashire	Indole derivatives
EP2968340A4 (en)	2013-03-15	2016-08-10	Intellikine Llc	COMBINING KINASE INHIBITORS AND USES THEREOF
WO2014153509A1 (en)	2013-03-22	2014-09-25	Millennium Pharmaceuticals, Inc.	Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
CA2922044A1 (en)	2013-10-18	2015-05-14	Medivation Technologies, Inc.	Pyrazolo-, imidazolo- and pyrrolo-pyridine or -pyrimidine derivatives as inhibitors o brutons kinase (btk)
CA2922058A1 (en)	2013-10-18	2015-04-23	Medivation Technologies, Inc.	Heterocyclic compounds and methods of use
GB201321146D0 (en) *	2013-11-29	2014-01-15	Cancer Rec Tech Ltd	Quinazoline compounds
KR102562866B1 (ko)	2014-11-14	2023-08-04	네르비아노 메디칼 사이언시스 에스.알.엘.	단백질 키나아제 억제제로서의 6-아미노-7-바이사이클로-7-데아자-퓨린 유도체
CA2974702C (en)	2015-01-26	2023-10-10	University Of Washington	Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases
WO2017027883A1 (en)	2015-08-13	2017-02-16	San Diego State University Research Foundation	Atropisomerism for increased kinase inhibitor selectivity
JP7337502B2 (ja) *	2015-09-16	2023-09-04	ロクソオンコロジー，インコーポレイテッド	がんの治療のためのｂｔｋ阻害剤としてのピラゾロピリミジン誘導体
WO2017160717A2 (en)	2016-03-15	2017-09-21	Memorial Sloan Kettering Cancer Center	Method of treating diseases using kinase modulators
SI3442535T1 (sl) *	2016-04-15	2023-01-31	Cancer Research Technology Limited	Heterociklične spojine kot zaviralci RET-kinaze
WO2017178844A1 (en) *	2016-04-15	2017-10-19	Cancer Research Technology Limited	Heterocyclic compounds as ret kinase inhibitors

2017
- 2017-04-18 WO PCT/GB2017/051076 patent/WO2017178844A1/en not_active Ceased
- 2017-04-18 EP EP17719687.0A patent/EP3442980B1/en active Active
- 2017-04-18 KR KR1020227013172A patent/KR102706837B1/ko active Active
- 2017-04-18 SM SM20210538T patent/SMT202100538T1/it unknown
- 2017-04-18 RS RS20211115A patent/RS62322B1/sr unknown
- 2017-04-18 DK DK17719687.0T patent/DK3442980T3/da active
- 2017-04-18 BR BR122023026297-2A patent/BR122023026297A2/pt not_active Application Discontinuation
- 2017-04-18 BR BR112018071097-0A patent/BR112018071097B1/pt not_active IP Right Cessation
- 2017-04-18 SG SG10201911665UA patent/SG10201911665UA/en unknown
- 2017-04-18 HR HRP20211362TT patent/HRP20211362T1/hr unknown
- 2017-04-18 PT PT177196870T patent/PT3442980T/pt unknown
- 2017-04-18 EP EP21172597.3A patent/EP3960180A1/en active Pending
- 2017-04-18 JP JP2018554114A patent/JP6943876B2/ja active Active
- 2017-04-18 RU RU2018138471A patent/RU2742115C2/ru active
- 2017-04-18 IL IL289793A patent/IL289793B2/en unknown
- 2017-04-18 KR KR1020247030356A patent/KR20240142568A/ko not_active Withdrawn
- 2017-04-18 US US16/093,854 patent/US10954241B2/en active Active
- 2017-04-18 MX MX2018012609A patent/MX387394B/es unknown
- 2017-04-18 PL PL17719687T patent/PL3442980T3/pl unknown
- 2017-04-18 KR KR1020187032842A patent/KR102390578B1/ko not_active Expired - Fee Related
- 2017-04-18 ES ES17719687T patent/ES2886587T3/es active Active
- 2017-04-18 IL IL297192A patent/IL297192A/en unknown
- 2017-04-18 HU HUE17719687A patent/HUE056135T2/hu unknown
- 2017-04-18 SI SI201730892T patent/SI3442980T1/sl unknown
- 2017-04-18 SG SG11201808878UA patent/SG11201808878UA/en unknown
- 2017-04-18 LT LTEPPCT/GB2017/051076T patent/LT3442980T/lt unknown
- 2017-04-18 CN CN201780031509.4A patent/CN109195972B/zh active Active
- 2017-04-18 CN CN202211269931.2A patent/CN115650985B/zh active Active
- 2017-04-18 AU AU2017250448A patent/AU2017250448C1/en active Active
2018
- 2018-10-07 IL IL262185A patent/IL262185B/en unknown
- 2018-10-15 MX MX2021013110A patent/MX2021013110A/es unknown
2020
- 2020-08-18 AU AU2020220079A patent/AU2020220079B2/en active Active
2021
- 2021-02-02 US US17/165,151 patent/US11548896B2/en active Active
- 2021-09-06 CY CY20211100784T patent/CY1124478T1/el unknown
- 2021-09-07 JP JP2021145468A patent/JP2021193108A/ja active Pending
2022
- 2022-06-06 AU AU2022203916A patent/AU2022203916A1/en not_active Abandoned
- 2022-11-22 US US17/992,049 patent/US20230339954A1/en not_active Abandoned
2023
- 2023-08-10 JP JP2023131211A patent/JP2023159230A/ja active Pending
2024
- 2024-12-03 US US18/967,321 patent/US20250236624A1/en active Pending

Also Published As

Publication number	Publication date
BR112018071097A2 (pt)	2019-01-29
US10954241B2 (en)	2021-03-23
AU2020220079A1 (en)	2020-09-03
CN115650985B (zh)	2024-08-02
RS62322B1 (sr)	2021-10-29
ES2886587T3 (es)	2021-12-20
JP2021193108A (ja)	2021-12-23
WO2017178844A1 (en)	2017-10-19
IL289793A (en)	2022-03-01
SMT202100538T1 (it)	2021-11-12
HUE056135T2 (hu)	2022-01-28
AU2022203916A1 (en)	2022-06-23
EP3960180A1 (en)	2022-03-02
PL3442980T3 (pl)	2021-12-06
PT3442980T (pt)	2021-09-13
SG11201808878UA (en)	2018-11-29
KR20220054894A (ko)	2022-05-03
IL262185B (en)	2022-02-01
RU2018138471A (ru)	2020-05-15
RU2018138471A3 (2)	2020-05-15
RU2742115C2 (ru)	2021-02-02
EP3442980B1 (en)	2021-06-09
JP6943876B2 (ja)	2021-10-06
IL262185A (en)	2018-11-29
IL289793B2 (en)	2023-03-01
CN109195972B (zh)	2022-10-28
US11548896B2 (en)	2023-01-10
MX2021013110A (es)	2021-11-17
CN115650985A (zh)	2023-01-31
MX2018012609A (es)	2019-08-01
CN109195972A (zh)	2019-01-11
BR112018071097B1 (pt)	2024-02-20
CA3020778A1 (en)	2017-10-19
KR20240142568A (ko)	2024-09-30
IL289793B (en)	2022-11-01
HRP20211362T1 (hr)	2021-11-26
IL297192A (en)	2022-12-01
MX387394B (es)	2025-03-18
JP2019515903A (ja)	2019-06-13
DK3442980T3 (da)	2021-08-30
JP2023159230A (ja)	2023-10-31
NZ747678A (en)	2024-05-31
EP3442980A1 (en)	2019-02-20
LT3442980T (lt)	2021-09-27
KR102706837B1 (ko)	2024-09-19
AU2017250448C1 (en)	2021-01-07
US20190106425A1 (en)	2019-04-11
SI3442980T1 (sl)	2021-11-30
KR102390578B1 (ko)	2022-04-26
US20230339954A1 (en)	2023-10-26
AU2017250448B2 (en)	2020-05-21
US20250236624A1 (en)	2025-07-24
SG10201911665UA (en)	2020-01-30
US20210155628A1 (en)	2021-05-27
AU2017250448A1 (en)	2018-11-01
KR20180134983A (ko)	2018-12-19
AU2020220079B2 (en)	2022-04-21
BR122023026297A2 (pt)	2024-01-16

Publication	Publication Date	Title
CY1124478T1 (el)	2022-07-22	Ετεροκυκλικες ενωσεις ως αναστολεις της κiνασης ret
CY1124239T1 (el)	2022-07-22	Ενωσεις αμινο-τριαζολοπυριδινης και χρηση αυτων στην αγωγη του καρκινου
CY1123395T1 (el)	2021-12-31	Ενωσεις καρβοξαμιδιων ινδολης χρησιμες ως αναστολεις κινασων
CY1124484T1 (el)	2022-07-22	2-ετεροαρυλο-3-οξο-2,3-διυδροπυριδαζινο-4-καρβοξαμιδια για τη θεραπευτικη αντιμετωπιση του καρκινου
CY1121433T1 (el)	2020-05-29	Παραγωγα δικυκλικων ετεροκυκλυλιων ως αναστολεις irak4
CY1125214T1 (el)	2023-06-09	Ενωσεις ν-((ετ)αρυλμεθυλ)-ετεροαρυλ-καρβοξαμιδιων ως αναστολεις καλλικρεϊνης πλασματος
CY1122550T1 (el)	2021-01-27	Αρυλικες, ετεροαρυλικες και ετεροκυκλικες ενωσεις για τη θεραπευτικη αντιμετωπιση των διαταραχων που διαμεσολαβουνται απο το συμπληρωμα
CY1122279T1 (el)	2020-10-14	Ενωσεις ναφθυριδινης αναστολεις κινασης jak
CY1123025T1 (el)	2021-10-29	Αναστολεις βρωμοεπικρατειας
CY1121706T1 (el)	2020-07-31	Ενωσεις υποκατασταθεισες διυδροϊσοκινολινονης
CY1120248T1 (el)	2019-07-10	Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου
CY1124680T1 (el)	2022-07-22	Παραγωγα 8-[6-[3-(αμινο)προποξυ]-3-πυριδυλο]-1-ισοπροπυλο-ιμιδαζο[4,5-c]κινολιν-2-ονης ως εκλεκτiκοι ρυθμιστες κινασης μεταλλαγμενης αταξιας τελαγγειεκτασιας (atm) για τη θεραπευτικη αγωγη του καρκινου
CY1122707T1 (el)	2021-03-12	Ετεροκυκλικοι αναστολεις γλουταμινασης
JOP20200315A1 (ar)	2020-12-07	مركبات بورينون واستخدامها في معالجة السرطان
CY1123494T1 (el)	2022-03-24	Enωσeiς etepoapyλo-kapboξamiδioy ως anaσtoλeiς thς ripk2
CY1126109T1 (el)	2023-11-15	Αναστολεις toy trpc6
BR112017009671A2 (pt)	2017-12-26	inibidores de ezh2 e usos destes
CY1120836T1 (el)	2019-12-11	Ενωσεις 1,3,4-θειαδιαζοαης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου
EP4104837A3 (en)	2023-04-26	Heterocyclic compounds as ret kinase inhibitors
CY1121063T1 (el)	2019-12-11	Αναστολεις της συνθασης της αλδοστερονης
CY1121650T1 (el)	2020-07-31	Αναστολεις συνθασης αλδοστερονης
JOP20210127A1 (ar)	2023-01-30	مركبات عطرية غير متجانسة كمثبطات Vanin
CY1116775T1 (el)	2017-03-15	Παραγωγα πυριμιδονης ως αναστολεις της ιστικης τρανσγλουταμινασης
CY1123880T1 (el)	2022-03-24	Καινοτομοι 5-ητ2 ανταγωνιστες
EA202190588A1 (ru)	2021-06-23	Гетероароматические соединения в качестве ингибиторов ванина